General Announcement::Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
29-Dec-2020 15:46:00
Status
New
Announcement Sub Title
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination
Announcement Reference
SG201229OTHRGDIM
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
29/12/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Attachments

PR_SGX_29122020.pdf
Total size =1148K